Tags

Type your tag names separated by a space and hit enter

Stenting and glycoprotein IIb/IIIa inhibition in patients with acute myocardial infarction undergoing percutaneous coronary intervention: findings from the global registry of acute coronary events (GRACE).
Catheter Cardiovasc Interv. 2003 Nov; 60(3):360-7.CC

Abstract

Stenting and GP IIb/IIIa inhibition are promising adjunctive therapies in PCI. The Global Registry of Acute Coronary Events (GRACE) is a registry of unselected patients with acute coronary syndromes, allowing for the study of treatments in a real-world environment. Data from GRACE patients with AMI who underwent PCI were analyzed. After adjusting for demographics, baseline characteristics, and previous medications, treatment with GP IIb/IIIa inhibitors and a stent and treatment with a stent alone were significant predictors of survival at 6 months. Stents were used in 90.9% of patients. GP IIb/IIIa inhibitors were used in 59.7%; in most cases they were started after the beginning of the procedure. The in-hospital death rate (7.6%) was highest in patients undergoing urgent PCI. Mortality at 6 months following PCI was 14.4% among patients who received neither GP IIb/IIIa inhibitors nor a stent, compared to patients who received both GP IIb/IIIa inhibitors and a stent (7.3%), GP IIb/IIIa inhibitors alone (12.8%), or a stent alone (6.7%).

Authors+Show Affiliations

Service de Cardiologie, Pitié-Salpêtrière Hospital, Paris, France. gilles.montalescot@psl.ap-hop-paris.frNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

14571488

Citation

Montalescot, Gilles, et al. "Stenting and Glycoprotein IIb/IIIa Inhibition in Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention: Findings From the Global Registry of Acute Coronary Events (GRACE)." Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions, vol. 60, no. 3, 2003, pp. 360-7.
Montalescot G, Van de Werf F, Gulba DC, et al. Stenting and glycoprotein IIb/IIIa inhibition in patients with acute myocardial infarction undergoing percutaneous coronary intervention: findings from the global registry of acute coronary events (GRACE). Catheter Cardiovasc Interv. 2003;60(3):360-7.
Montalescot, G., Van de Werf, F., Gulba, D. C., Avezum, A., Brieger, D., Kennelly, B. M., Mazurek, T., Spencer, F., White, K., & Gore, J. M. (2003). Stenting and glycoprotein IIb/IIIa inhibition in patients with acute myocardial infarction undergoing percutaneous coronary intervention: findings from the global registry of acute coronary events (GRACE). Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions, 60(3), 360-7.
Montalescot G, et al. Stenting and Glycoprotein IIb/IIIa Inhibition in Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention: Findings From the Global Registry of Acute Coronary Events (GRACE). Catheter Cardiovasc Interv. 2003;60(3):360-7. PubMed PMID: 14571488.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Stenting and glycoprotein IIb/IIIa inhibition in patients with acute myocardial infarction undergoing percutaneous coronary intervention: findings from the global registry of acute coronary events (GRACE). AU - Montalescot,Gilles, AU - Van de Werf,Frans, AU - Gulba,Dietrich C, AU - Avezum,Alvaro, AU - Brieger,David, AU - Kennelly,Brian M, AU - Mazurek,Tomasz, AU - Spencer,Frederick, AU - White,Kami, AU - Gore,Joel M, AU - ,, PY - 2003/10/23/pubmed PY - 2004/3/20/medline PY - 2003/10/23/entrez SP - 360 EP - 7 JF - Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions JO - Catheter Cardiovasc Interv VL - 60 IS - 3 N2 - Stenting and GP IIb/IIIa inhibition are promising adjunctive therapies in PCI. The Global Registry of Acute Coronary Events (GRACE) is a registry of unselected patients with acute coronary syndromes, allowing for the study of treatments in a real-world environment. Data from GRACE patients with AMI who underwent PCI were analyzed. After adjusting for demographics, baseline characteristics, and previous medications, treatment with GP IIb/IIIa inhibitors and a stent and treatment with a stent alone were significant predictors of survival at 6 months. Stents were used in 90.9% of patients. GP IIb/IIIa inhibitors were used in 59.7%; in most cases they were started after the beginning of the procedure. The in-hospital death rate (7.6%) was highest in patients undergoing urgent PCI. Mortality at 6 months following PCI was 14.4% among patients who received neither GP IIb/IIIa inhibitors nor a stent, compared to patients who received both GP IIb/IIIa inhibitors and a stent (7.3%), GP IIb/IIIa inhibitors alone (12.8%), or a stent alone (6.7%). SN - 1522-1946 UR - https://www.unboundmedicine.com/medline/citation/14571488/Stenting_and_glycoprotein_IIb/IIIa_inhibition_in_patients_with_acute_myocardial_infarction_undergoing_percutaneous_coronary_intervention:_findings_from_the_global_registry_of_acute_coronary_events__GRACE__ L2 - https://doi.org/10.1002/ccd.10653 DB - PRIME DP - Unbound Medicine ER -